{
    "clinical_study": {
        "@rank": "151171", 
        "arm_group": [
            {
                "arm_group_label": "Radiotherapy alone", 
                "arm_group_type": "Active Comparator", 
                "description": "Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy"
            }, 
            {
                "arm_group_label": "Concurrent chemoradiation", 
                "arm_group_type": "Experimental", 
                "description": "Concurrent chemoradiation\nChemotherapy:\nMethotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to prove the superiority of concurrent chemoradiation compared\n      with radiotherapy alone in patients with low risk NK/T-cell lymphoma."
        }, 
        "brief_title": "Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Extranodal NK/T-cell Lymphoma, Nasal Type", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, T-Cell", 
                "Lymphoma, Extranodal NK-T-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "Radiotherapy alone is commonly used in NK/T-cell lymphoma without adverse risk including\n      lymph node involvement, local invasion, B symptoms and high LDH level. Recently,\n      methotrexate was prove to be a radiosensitizer in NK/T-cell lymphoma cells. Therefore, the\n      investigators aim to verify the superiority and safety of weekly methotrexate in combination\n      with radiotherapy in a randomized phase II study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age range 18-75 years old\n\n          -  Histological confirmed, previously untreated stage IE nasal NK/T cell lymphoma\n             without following risk factors including local invasion, B symptoms and high LDH\n             level\n\n          -  ECOG performance status 0-1\n\n          -  Life expectancy of more than 3 months\n\n          -  Adequate bone marrow and organ functions\n\n        Exclusion Criteria:\n\n          -  non-nasal NK/T-cell lymphoma\n\n          -  Prior exposure of methotrexate\n\n          -  With third space effusion\n\n          -  Pregnant or lactating women\n\n          -  Serious uncontrolled diseases and intercurrent infection\n\n          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma\n             in-situ of uterine cervix"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "4", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01667289", 
            "org_study_id": "LMTG 12-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Radiotherapy alone", 
                    "Concurrent chemoradiation"
                ], 
                "description": "Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy", 
                "intervention_name": "Radiotherapy alone", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Concurrent chemoradiation", 
                "description": "Concurrent chemoradiation\nChemotherapy:\nMethotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy", 
                "intervention_name": "Concurrent chemoradiation", 
                "intervention_type": "Drug", 
                "other_name": "MTX"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methotrexate"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "NK/T-cell lymphoma", 
            "Methotrexate", 
            "Radiotherapy", 
            "Concurrent chemoradiation"
        ], 
        "lastchanged_date": "March 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Fudan University Cancer Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Phase II Study of Comparing Radiotherapy Alone With Concurrent Chemoradiation in Patients With Low Risk NK/T-cell Lymphoma", 
        "overall_official": {
            "affiliation": "Fudan University", 
            "last_name": "Ye Guo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "3-year Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01667289"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Ye Guo", 
            "investigator_title": "Assocaite Director of Medical Oncology Department", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall response rate", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "3-year overall survival", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013", 
        "why_stopped": "unexpected high grade of mucositis observed"
    }
}